SCHEMBL5359255

SCHEMBL5359255

CO[C@@H]1C[C@@H](C(=O)N(C)C)N(C(=O)OC(C)(C)C)C1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
UCHL1 P09936 1/20 0.54
NR1H2 P55055 1/20 0.35
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
AVPR2 P30518 1/20 0.34
HSD17B10 Q99714 1/20 0.33
MCL1 Q07820 1/20 0.33
P2RX3 P56373 1/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
USP30 Q70CQ3 1/20 0.32
HSD11B1 P28845 1/20 0.32
HTRA1 Q92743 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18538108 0.89 UCHL1 (0.53) UCHL1NR1H2CYP1A2POLBCYP3A4
SCHEMBL25619159 0.89 UCHL1 (0.53) UCHL1NR1H2CYP1A2POLBCYP3A4
SCHEMBL27393752 0.89 UCHL1 (0.53) UCHL1NR1H2CYP1A2POLBCYP3A4
SCHEMBL31340923 0.89 UCHL1 (0.53) UCHL1NR1H2CYP1A2POLBCYP3A4
SCHEMBL30501862 0.89 UCHL1 (0.53) UCHL1NR1H2CYP1A2POLBCYP3A4
SCHEMBL30955441 0.86 UCHL1 (0.43) UCHL1NR1H2CYP1A2POLBCYP3A4
SCHEMBL5352509 0.85 UCHL1 (0.42) UCHL1NR1H2CYP1A2POLBCYP3A4
SCHEMBL15116712 0.84 UCHL1 (0.47) UCHL1NR1H2CYP1A2POLBCYP3A4
SCHEMBL239963 0.84 UCHL1 (0.49) UCHL1NR1H2CYP1A2POLBCYP3A4
SCHEMBL17783113 0.84 UCHL1 (0.49) UCHL1NR1H2CYP1A2POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7297692-B2 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2007-11-20 US disclosed
US-20070004703-A1 NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI-AVENTIS (FR) 2007-01-04 US disclosed
US-7129240-B2 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2006-10-31 US disclosed
US-20040209938-A1 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them SANOFI (FR) 2004-10-21 US disclosed
US-6730695-B2 TREATMENT OF HYPERTENSION, CENTRAL NERVOUS SYSTEM DISORDERS SANOFI-SYNTHELABO (FR) 2004-05-04 US disclosed
US-20030114683-A1 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors SANOFI (FR) 2003-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114683-A1 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors AVPR1B, AVPR1A, AVPR2 UCHL1 4337/4885NR1H2 761/4885CYP1A2 1241/4885
US-20040209938-A1 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them AVPR2, AVPR1B, AVPR1A UCHL1 4504/4885NR1H2 528/4885CYP1A2 519/4885
US-20070004703-A1 NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVPR1B, AVPR2, AVPR1A UCHL1 4599/4885NR1H2 655/4885CYP1A2 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.